Nature Medicine published Phase 1 results of Innovent Biologics’ anti-CLDN18.2 ADC (IBI343) in patients with advanced gastric/gastroesophageal junction adenocarcinoma

CAR-T Digest - August 2020

Weekly Digest - July 2025

16 July 2025: Nature Medicine published Phase 1 results of Innovent Biologics’ anti-CLDN18.2 ADC (IBI343) in patients with advanced gastric/gastroesophageal junction adenocarcinoma

Phase 1 results of Innovent Biologics’ anti-CLDN18.2 ADC, IBI343, for advanced gastric/gastroesophageal junction adenocarcinoma were published in Nature Medicine, showing promising efficacy and low GI toxicity in 116 patients
Based on Phase 1 findings, a multi-regional Phase 3 trial (G-HOPE-001) was launched in 2024 to compare IBI343 with standard treatment in advanced G/GEJ cancer
IBI343 is a Fc-silent antibody-drug conjugate targeting CLDN18.2, a protein overexpressed in various cancers including gastric (60–80%), pancreatic, esophageal, and lung cancers
With China contributing nearly 40% of global gastric cancer deaths, IBI343 represents a significant step in addressing a major unmet medical need in oncology